FDA Grants BCMA CAR T-Cell Therapy Breakthrough Designation in Myeloma

November 16, 2017 – The FDA has granted bb2121 a breakthrough therapy designation for previously treated patients with relapsed/refractory multiple myeloma, according to Celgene Corporation and bluebird bio, the companies developing the anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy. In a press release, the companies reported that the investigational agent had also been awarded PRIority MEdicines (PRIME) eligibility by … (leggi tutto)